Miglustat Dipharma (Miglustat)

• Miglustat is used as substrate reduction therapy for lysosomal storage disorders, targeting the accumulation of glycosphingolipids.
• Niemann-Pick disease type C: reduces glycosphingolipid buildup, helping to stabilize neurological function.
• Gaucher disease type 1: lowers substrate accumulation in macrophages, improving hematologic and visceral symptoms.
• Rare lysosomal storage disorders: may be employed off‑label as substrate reduction therapy under specialist supervision.

• Miglustat inhibits the enzyme glucosylceramide synthase, the first step in the biosynthesis of glycosphingolipids. By blocking this pathway, the drug reduces the production of glucosylceramide and downstream complex sphingolipids, decreasing substrate accumulation in cells affected by Niemann‑Pick disease type C and Gaucher disease type 1.

Miglustat may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious events.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: feeling of sickness, may affect appetite.
• Abdominal pain: cramping or discomfort in the stomach area.
• Weight loss: gradual reduction in body weight.
• Flatulence: increased gas production.
• Taste alteration: metallic or altered taste perception.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain.
• Severe hypoglycemia: low blood sugar, especially in patients with diabetes.
• Allergic reactions: rash, itching, or swelling that may require medical attention.
• Elevated liver enzymes: potential liver injury, monitored via blood tests.
• Depression or mood changes: new or worsening psychiatric symptoms.
• Seizures: rare neurologic events requiring urgent care.

• Before initiating Miglustat therapy, clinicians should consider several safety measures.
• Monitor liver function: obtain baseline tests and repeat periodically.
• Assess renal function: adjust use in patients with impaired kidneys.
• Evaluate gastrointestinal tolerance: counsel patients on diet and hydration.
• Avoid in patients with known hypersensitivity to miglustat or its excipients.
• Pregnancy: risk category unknown; discuss potential benefits and risks with the prescriber.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Miglustat can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may markedly reduce miglustat exposure.
• Co‑administration with other substrate reduction agents: increases risk of toxicity.
• Antidiabetic drugs (e.g., insulin, sulfonylureas): may potentiate hypoglycemia.

Moderate Interactions (Monitor Closely)

• Warfarin: may affect INR; monitor coagulation parameters.
• Antiepileptic drugs: can alter miglustat plasma levels.
• Oral contraceptives: possible reduction in contraceptive effectiveness; consider additional barrier methods.